You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a novel highly effective influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. STTR Phase I: 24x7 mobile wireless monitoring of patient's vitals to proactively manage disease recovery

    SBC: Argosy Omnimedia, Inc.            Topic: SH

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is found in the proposed technology development that facilitates direct, ubiquitous acquisition of key biomedical data, with little or no human intervention or introduction of errors, has the potential to reduce the costs of healthcare and to revolutionize healthcare delivery throughout our so ...

    STTR Phase I 2014 National Science Foundation
  4. STTR Phase I: Ferrofluidic enclosures for enhanced control of thermal and magnetic fields in spin-stabilized atomic micro-devices

    SBC: COMMET LLC            Topic: EW

    The broader impact/commercial potential of this project is determined by new consumer products and new industries which would flourish on portable and reliable atomic clocks, gyroscopes, and magnetometers when they become available. Proposed compact thermal and magnetic enclosure reduces the most bulky part of such devices and provides an avenue for further miniaturization. A chip-scale atomic clo ...

    STTR Phase I 2014 National Science Foundation
  5. STTR Phase I: Self-Assembled Conductive Polymer Nanostructures as Coating Additives for Carbon Fiber Reinforced Composite Aircraft

    SBC: Polydrop LLC            Topic: NM

    This Small Business Technology Transfer Phase I project aims to demonstrate the feasibility of new nanostructured conductive additives for use in antistatic aerospace high-performance coatings. Static charge buildup from the environment is a critical problem for vehicles which utilize lightweight components constructed from non-conductive plastic or composite materials. Static charge buildup inter ...

    STTR Phase I 2014 National Science Foundation
  6. STTR Phase I: Using Nanoparticle Oxide Coatings to Increase Cycle Life of Cathode Materials for Li-Ion Batteries

    SBC: SolRayo            Topic: MM

    This Small Business Technology Transfer Phase I project will seek to improve the performance of the cathode materials used in lithium-ion (Li-ion) batteries. LiCoO2 is the primary cathode material, but it is relatively expensive, and has safety concerns. A safer alternative is LiMn2O4, but its utilization is limited by a relatively higher fade capacity; i.e. decrease in capacity with repeated cy ...

    STTR Phase I 2010 National Science Foundation
  7. GalT-KO Pigs Expressing Primate CD47 to Facilitate Organ Xenografts

    SBC: MINITUBE OF AMERICA            Topic: NIAID

    DESCRIPTION (provided by applicant): Xenotransplantation with pig organs offers the best near term hope for satisfying the limitation imposed by shortage of human organs. Although hyperacute rejection of pig organs in primate recipients has been overcome by the production of (-1,3-galactosyltransferase knockout (GalT-KO) pigs, experiments to date with GalT-KO organs strongly suggest that clinical ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Cotton Rat: Animal Model Predictive of Clinical Responses to HSV Vaccines

    SBC: VIRION SYSTEMS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Genital herpes is one of the most prevalent sexually transmitted infections worldwide and is associated with substantial morbidity. The impact of genital herpes as a public health threat is amplified because of its epidemiologic synergy with HIV. Epidemiological studies consistently demonstrate that HSV infection increases the risk of HIV transmission and acqu ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Early detection of prostate cancer in urine

    SBC: New Horizons Diagnostics            Topic: NCI

    DESCRIPTION (provided by applicant): Prostate cancer is the second most common cancer in men, and the second leading cause of cancer death. However, when prostate cancer is diagnosed in its early stages, it can be effectively treated and cured. Combined with the digital rectal examination, the prostate specific antigen (PSA) test has been widely used to detect prostate cancer in its early stages. ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. COPE-P: Shared Decision-Making Aid for Patients Regarding Chronic Opioid Therapy

    SBC: TALARIA, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Use of prescription opioids for chronic non-cancer pain (CNCP) has escalated rapidly in the past two decades. Prescription opioid abuse is the fastest growing form of drug abuse, and prescription opioids are now the top cause of accidental drug overdose. The FDA plans to issue a Risk Evaluation and Mitigation Strategy to manage risks associated with chronic opi ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government